Dasatinib is a potent tyrosine kinase inhibitor that was established to be utilized in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia due to its ability to inhibit BCR-ABL tyrosine kinase. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.